Mozart Therapeutics Expands Executive Leadership Team

Mozart Therapeutics, a developer of CD8 Treg modulators for the treatment of autoimmune and inflammatory disease, expanded its executive leadership team with the appointments of Jason Chien, chief medical officer, and Russ Hawkinson as chief financial officer. 

Chien brings nearly 30 years of experience in immunology and infectious diseases from his work in academia, healthcare, and the biopharmaceutical industry. He previously served as vice president of respiratory infection R&D strategy and infectious diseases clinical translational sciences at Janssen, where he was responsible for overseeing the development of a preclinical and clinical pipeline in infectious diseases and prior to that led multiple immunology programs during his tenure at Gilead.

Hawkinson brings over 20 years of experience guiding financial strategy in the life science industry. He recently served as senior vice president, finance at Silverback Therapeutics, where he helped complete the company’s private offerings, IPO, and merger of the company with ARS Pharmaceuticals in 2022.

“Jason Chien and Russ Hawkinson are industry veterans with established track records and a wealth of strategic and operating experience,” said Katie Fanning, President, and CEO at Mozart Therapeutics. “They both join Mozart at an exciting time as we prepare to enter the clinic with our lead program, MTX-101, in the first half of next year and advance our pipeline of first-in-class CD8 Treg modulators.”